Economic burden of immunotherapy as second-line treatment of patients with advanced non-small-cell lung cancer at a Latin American oncology center
| Autor: | Feliciano Barrón, Oscar Gerardo Arrieta Rodriguez, L. Cabrera, Andres Felipe Cardona Zorrilla |
|---|---|
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 37:e18376-e18376 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | e18376 Background: Lung cancer is the leading cause of cancer-related mortality in México and worldwide. More than 80 percent of lung cancers are classified as non-small cell lung cancer (NSCLC). Immunotherapy has become integrated into the treatment of patients with specific genetic alterations, which has led to improvements in survival and quality of life. Pembrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. Methods: A retrospective study of medical records of 60 patients treated with immunotherapy as second-line treatment of advanced non-small-cell lung cancer was conducted at the National Institute of Cancerology (INCAN) in Mexico during 2016-2018. PD-L1 biomarker was not mandatory for receiving immunotherapy. The costs associated with the total costs of tretament were estimated as a mean value with confidence intervals of 95% confidence by costing the elements of treatment of the disease and adverse events as well the frequency of consultations, hospital stays, and monitoring obtained in the records. Costs are presented in US dollars. Results: The total mean monthly cost during immunotherapy was $1,649 (95% confidence interval [CI] = $1,484–$1,814), of which 93.8% represented immunotherapy costs, 5.4% drug application and monitoring, 0.8% adverse events treatment. We identified 30 potential patients per year candidates to receive immunotherapy as second line. From which the expected costs of treatment will be $49,476 [CI] = $44,528–$57,392), of which $41,766 are immunotherapy costs, application and monitoring represent $2,400 and the rest for adverse events. Conclusions: The therapeutic approach for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations has been revolutionized by the approval of new more efficacious drugs like pembrolizumab. Healthcare costs during immunotherapy treatment with pembrolizumab were largely attributed to anti-cancer therapy and less for adverse events. Pembrolizumab as second-line treatment of patients with advanced non-small-cell lung cancer, prolong overall survival, leading to fewer adverse events than chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|